( March 23, 2026, 2:32 PM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court on March 23 granted the U.S. government’s motion to participate in oral arguments when it considers the standard for the inducement of infringement to be applied in medical patent cases, including in “skinny label cases” involving allegedly noninfringing use; on March 20, the patent-holding biopharmaceutical entities filed their merits brief, arguing that statements made by a bioequivalent maker plausibly allege induced infringement....